Clopidogrel Has No clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 Substrate Simvastatin

Drug Metabolism and Disposition

Volumn 43, Issue 11, 2015, Pages 1655-1660

  Itkonen, Matti K ^a   Tornio, Aleksi ^a   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a   Niemi, Mikko ^a   Backman, Janne T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 3A4; CYTOSINE; PLACEBO; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; THYMINE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; TICLOPIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; ANALOGS AND DERIVATIVES; BLOOD; DRUG INTERACTION; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; SIMVASTATIN; TICLOPIDINE; YOUNG ADULT;

EID: 84946206740     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.065938     Document Type: Article

References (43)

1. Armitage J (2007) The safety of statins in clinical practice. Lancet 370:1781-1790.
2. Backman JT, Kyrklund C, Kivistö KT, Wang JS, and Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122-129.
3. Bhindi R, Ormerod O, Newton J., Banning AP, and Testa L (2008) Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 101:915-925.
4. Delavenne X, Basset T, Zufferey P., Malouk N, Laporte S, and Mismetti P (2010) Ultraperformance LC MS/MS method for quantification of clopidogrel active metabolite. J Sep Sci 33:1968-1972.
5. Floyd JS, Kaspera R, Marciante K.D., Weiss NS, Heckbert SR, Lumley T, Wiggins K.L., Tamraz B., Kwok PY, and Totah RA, et al. (2012) A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther 91:896-904.
6. Giacomini KM, Balimane PV, Cho S.K., Eadon M., Edeki T, Hillgren KM, Huang S.M., Sugiyama Y., Weitz D, and Wen Y, et al.; International Transporter Consortium (2013) International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther 94:23-26.
7. Ho RH, Tirona RG, Leake B.F., Glaeser H., Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
8. Holmberg MT, Tornio A, Neuvonen M., Neuvonen PJ, Backman JT, and Niemi M (2014) Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin Pharmacol Ther 95: 307-313.
9. Huang L, Wang Y, and Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742.
10. Huang SM, Temple R, Throckmorton D.C., and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81: 298-304.
11. Ichimaru N, Takahara S, Kokado Y., Wang JD, Hatori M, Kameoka H, Inoue T., and Okuyama A (2001) Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 158:417-423.
12. Kajosaari LI, Laitila J, Neuvonen P.J., and Backman JT (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256.
13. Kantola T, Kivistö KT, and Neuvonen PJ (1999) Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 54:851-855.
14. Keskitalo JE, Pasanen MK, Neuvonen P.J., and Niemi M (2009a) Different effects of the ABCG2 c.421C.A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617-1624.
15. Keskitalo JE, Zolk O, Fromm M.F., Kurkinen KJ, Neuvonen PJ, and Niemi M (2009b) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203.
16. Kitamura S, Maeda K, Wang Y., and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
17. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, and Neuvonen PJ (2000) Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68:592-597.
18. Lilja JJ, Kivistö KT, and Neuvonen PJ (1998) Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477-483.
19. Lilja JJ, Neuvonen M, and Neuvonen PJ (2004) Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58:56-60.
20. Link E, Parish S, Armitage J., Bowman L, Heath S, Matsuda F., Gut I, Lathrop M, and Collins R; SEARCH Collaborative Group (2008) SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 359:789-799.
21. Mauro VF (1993) Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24:195-202.
22. Mück W (1998) Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 56 (Suppl 1):15-23, discussion 33.
23. Neuvonen PJ, Kantola T, and Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63: 332-341.
24. Neuvonen PJ, Niemi M, and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581.
25. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
26. Pasanen MK, Backman JT, Neuvonen P.J., and Niemi M (2006b) Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 62:409-415.
27. Pasanen MK, Fredrikson H, Neuvonen P.J., and Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-733.
28. Pasanen MK, Neuvonen M, Neuvonen P.J., and Niemi M (2006a) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16: 873-879.
29. Pinheiro LF, França CN, Izar M.C., Barbosa SP, Bianco HT, Kasmas SH, Mendes G.D., Povoa RM, and Fonseca FA (2012) Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. Int J Cardiol 158: 125-129.
30. Prueksaritanont T, Gorham LM, Ma B, Liu L., Yu X, Zhao JJ, Slaughter D.E., Arison BH, and Vyas KP (1997) In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25: 1191-1199.
31. Prueksaritanont T, Ma B, and Yu N (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 56: 120-124.
32. Ramsey LB, Johnson SG, Caudle K.E., Haidar CE, Voora D, Wilke RA, Maxwell W.D., McLeod HL, Krauss RM, and Roden DM, et al. (2014) The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 96:423-428.
33. Remsberg CM, Frassetto LA, Okochi H, and Benet LZ (2013) Identification of a new drug-drug interaction between clopidogrel and rosuvastatin mediated through OATP1B1. Clin Pharmacol Ther 93 (Supplement 1):S8.
34. Shitara Y, Hirano M, Sato H., and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
35. Siepmann T, Heinke D, Kepplinger J., Barlinn K, Gehrisch S, Grählert X, Schwanebeck U., Reichmann H, Puetz V, and Bodechtel U, et al. (2014) Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study. Br J Clin Pharmacol 78:1058-1066.
36. Tamraz B, Fukushima H, Wolfe A.R., Kaspera R., Totah RA, Floyd JS, Ma B, Chu C., Marciante KD, and Heckbert SR, et al. (2013) OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics 23: 355-364.
37. Tornio A, Filppula AM, Kailari O, Neuvonen M., Nyrönen TH, Tapaninen T., Neuvonen PJ, Niemi M, and Backman JT (2014) Glucuronidation converts clopidogrel to a strong timedependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 96:498-507.
38. Vickers S, Duncan CA, Chen I.W., Rosegay A., and Duggan DE (1990a) Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18:138-145.
39. Vickers S, Duncan CA, Vyas K.P., Kari PH, Arison B, Prakash SR, Ramjit H.G., Pitzenberger SM, Stokker G, and Duggan DE (1990b) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 18:476-483.
40. Vinholt P, Poulsen TS, Korsholm L, Kristensen S.R., Hallas J., Damkier P, and Mickley H (2005) The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost 94:438-443.
41. Wang JS, Neuvonen M, Wen X., Backman JT, and Neuvonen PJ (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352-1356.
42. Wilke RA, Ramsey LB, Johnson S.G., Maxwell WD, McLeod HL, Voora D, Krauss R.M., Roden DM, Feng Q, and Cooper-Dehoff RM, et al.; Clinical Pharmacogenomics Implementation Consortium (CPIC) (2012) The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 92:112-117.
43. Zhao JJ, Xie IH, Yang A.Y., Roadcap BA, and Rogers JD (2000) Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J Mass Spectrom 35:1133-1143.